公司资料
Amarin Corporation 股价、新闻与催化剂
- 股票代码:
- AMRN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Ireland and listed in the U
股票表现
14.01 USD (-0.43%)
收盘价
最后更新: 2026年8月17日
303M USD
市值
股价为何变动
As of Aug 17, 2026, AMRN closed down 0.43% at $14.01. No new same-company headline was identified in the current news window.
公司概览
Cardiovascular Pharmaceutical Company
Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities.
Partnered International Model
Amarin shifted to a fully partnered international commercial strategy, including a long-term license and supply agreement with Recordati for Europe-focused commercialization across 59 countries. This model reduced operating expenses while allowing partners with local expertise to drive pricing, reimbursement, market access, and adoption.
U.S. Branded IPE Presence
In the United States, Amarin continues to maintain a leading branded IPE position despite generic competition. The company's U.S. IPE market share increased to 48% in the second quarter of 2026, while branded VASCEPA prescriptions rose year over year.
Strategic Position
Amarin is best understood as a focused cardiovascular company transitioning from direct global commercialization to a leaner partner-led international model. Its near-term performance depends on international volume growth, stable U.S. branded share, disciplined operating expenses, and positive cash flow generation.
未来催化剂
- Near-term commercialization progress in Singapore and South Korea.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。